MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 (MAPPYACTS2)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05691608 |
Recruitment Status :
Recruiting
First Posted : January 20, 2023
Last Update Posted : January 20, 2023
|
Tracking Information | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | December 12, 2022 | ||||||||||
First Posted Date ICMJE | January 20, 2023 | ||||||||||
Last Update Posted Date | January 20, 2023 | ||||||||||
Actual Study Start Date ICMJE | September 9, 2022 | ||||||||||
Estimated Primary Completion Date | September 9, 2030 (Final data collection date for primary outcome measure) | ||||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||||
Change History | No Changes Posted | ||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||
Descriptive Information | |||||||||||
Brief Title ICMJE | MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 | ||||||||||
Official Title ICMJE | MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 | ||||||||||
Brief Summary | FMG2025 continues the previous efforts to propose treatment for patients based on the molecular characteristics of their tumor at treatment failure in cancer precision medicine trials within standard of care in France. However, whereas FMG2025 is a descriptive effort providing the basis for clinical decisions, MAPPYACTS 2 will translate these findings to clinical actions. The symbiosis is critical to advance patient care. Since 2012, the molecular profiling trials "MOlecular Screening for CAncer Treatment Optimization" (MOSCATO-01) and "MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification" (MAPPYACTS) have included pediatric and adolescent patients with recurrent or refractory malignancy that underwent on-purpose biopsy or surgical intervention. Whole Exome Sequencing of tumor and normal tissue and RNA Sequencing of tumor tissue have been applied to detect genomic alterations that could lead to an adapted targeted treatment. Furthermore, ancillary studies were associated exploring circulating tumor DNA, the immune contexture of tumors and developing Patient-Derived Xenografts (PDX). The FMG2025 project transfers the molecular profiling of advanced pediatric cancers into a global approach that is now considered standard of care in France. Subsequent clinical recommendations and decisions will be made based on discussions with biologists, scientist and physicians in the molecular and clinical molecular tumor boards. Associated ancillary research studies and links to clinical interventional studies remain essential elements of the program to provide clinical, translational and basic research in order to improve scientific knowledge. The program is articulated in two main parts that are closely interacting: FMG2025 - Cancers et leucémies pédiatriques en échec de traitement or equivalent international projects that cover the sequencing of tumor and blood samples and provide molecular reports. The clinical study MAPPYACTS 2 that provides clinical and therapeutic discussions of the sequencing results and therapy recommendations via the clinical molecular tumor board reports. It collects molecular and comprehensive clinical data of the patients registered in FMG2025 or equivalent international projects and thereby constitutes the critical link to clinical interventional studies and its sponsors ensuring facilitated access to these trials. It also covers and coordinates ancillary research studies. |
||||||||||
Detailed Description | MAPPYACTS 2 is a prospective international multicentric clinical study to provide clinical therapeutic recommendations, to set up the molecular and comprehensive clinical database of patients with relapsed or refractory pediatric malignancies in FMG2025 - Cancers et leucémies pédiatriques en échec de traitement or equivalent international projects, to collect the follow-up data on treatment and patients' outcome, in order to determine the outcome of the program in regard to benefit to the patient, all the patients and to health care. It will also serve as a central link to interventional study platforms and international precision medicine programs, and to cover and coordinate ancillary research studies that lead to improved treatment and outcome for children with advanced malignancies. Subsequent clinical recommendations and decisions will be made based on discussions with biologists, scientists and physicians in the molecular and clinical molecular tumor boards run by the MAPPYACTS 2 study teams. Associated ancillary research studies and links to clinical interventional studies are essential components of the program to perform clinical, translational and basic research in order to generate scientific knowledge and develop new treatment strategies that improve outcome of these patients. Research projects will be discussed and agreed on in the MAPPYACTS 2 study committee. |
||||||||||
Study Type ICMJE | Interventional | ||||||||||
Study Phase ICMJE | Not Applicable | ||||||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Diagnostic |
||||||||||
Condition ICMJE |
|
||||||||||
Intervention ICMJE | Biological: Solid tumor and CT DNA
Biopsy and blood sample
|
||||||||||
Study Arms ICMJE | Experimental: Patient with solid tumor or leukemia (no treatment)
Patient with solid tumor or leukemia (no treatment)
Intervention: Biological: Solid tumor and CT DNA
|
||||||||||
Publications * | Not Provided | ||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||
Recruitment Information | |||||||||||
Recruitment Status ICMJE | Recruiting | ||||||||||
Estimated Enrollment ICMJE |
1800 | ||||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||||
Estimated Study Completion Date ICMJE | September 9, 2030 | ||||||||||
Estimated Primary Completion Date | September 9, 2030 (Final data collection date for primary outcome measure) | ||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||
Sex/Gender ICMJE |
|
||||||||||
Ages ICMJE | 6 Years to 25 Years (Child, Adult) | ||||||||||
Accepts Healthy Volunteers ICMJE | Yes | ||||||||||
Contacts ICMJE |
|
||||||||||
Listed Location Countries ICMJE | France | ||||||||||
Removed Location Countries | |||||||||||
Administrative Information | |||||||||||
NCT Number ICMJE | NCT05691608 | ||||||||||
Other Study ID Numbers ICMJE | 2021-A02990-41 2021-3321 ( Other Identifier: CSET NUMBER ) |
||||||||||
Has Data Monitoring Committee | No | ||||||||||
U.S. FDA-regulated Product |
|
||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||
Current Responsible Party | Gustave Roussy, Cancer Campus, Grand Paris | ||||||||||
Original Responsible Party | Same as current | ||||||||||
Current Study Sponsor ICMJE | Gustave Roussy, Cancer Campus, Grand Paris | ||||||||||
Original Study Sponsor ICMJE | Same as current | ||||||||||
Collaborators ICMJE | Not Provided | ||||||||||
Investigators ICMJE |
|
||||||||||
PRS Account | Gustave Roussy, Cancer Campus, Grand Paris | ||||||||||
Verification Date | January 2023 | ||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |